Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Frontiers in Oncology|April 1, 2022
Development and Validation of a Novel Prognostic Nomogram Combined With Desmoplastic Reaction for Synchronous Colorectal Peritoneal MetastasisXiusen Qin, Mingpeng Zhao, Weihao Deng, et al.
Journal of Hazardous Materials|April 11, 2024
Physiological and molecular mechanisms of ZnO quantum dots mitigating cadmium stress in Salvia miltiorrhizaSongyue Chai, Weihao Deng, Jianping Yang, et al.
International Journal of Cancer|July 6, 2023
China special issue on gastrointestinal tumors-Radiological features of pathological complete response in mismatch repair deficient colorectal cancer after neoadjuvant PD-1 blockade: A post hoc analysis of the PICC phase II trialWuteng Cao, Huabin Hu, Jiao Li, et al.
Gastroenterology Report|April 3, 2024
Testing region selection and prognostic analysis of <i>MLH1</i> promoter methylation in colorectal cancer in ChinaXiaoli Tan, Yongzhen Fang, Xinjuan Fan, et al.
International Immunopharmacology|April 7, 2025
APOC1 expressed in macrophages promotes the pulmonary metastasis of colorectal cancer via CCL2/CCL5Fei Qin, Haosheng Zheng, Jiayan Wu, et al.
Journal of Clinical Pathology|December 6, 2023
Head-to-head comparative study: evaluating three panels for MSI-PCR testing in patients with colorectal and gastric cancerXinhui Fu, Jinglin Huang, Xinjuan Fan, et al.
International Journal of Cancer|April 10, 2024
Prognosis and immunotherapy efficacy in dMMR&MSS colorectal cancer patients and an MSI status predicting modelXinhui Fu, Jinglin Huang, Junling Zhu, et al.
The Lancet. Gastroenterology & Hepatology|October 24, 2021
Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trialHuabin Hu, Liang Kang, Jianwei Zhang, et al.
The Lancet. Oncology|July 1, 2026
Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trialHuabin Hu, Xutao Shen, Yunfeng Li, et al.
Pageof 2